Regulatory requirements for approval of biological products as per CDSCO in Indian comparison with South Korea

Ashok kumar P; Divija P M; Reshma B R; Bhoomika K R; Ramya Shree R

doi:10.30574/wjarr.2023.20.1.2079

eISSN: 2581-9615 || CODEN: WJARAI || Impact Factor 8.2 || CrossRef DOI

Research and review articles are invited for publication in March 2026 (Volume 29, Issue 3) Submit manuscript

Regulatory requirements for approval of biological products as per CDSCO in Indian comparison with South Korea

Ashok kumar P ^*, Divija P M, Reshma B R, Bhoomika K R and Ramya Shree R

Department of Pharmaceutical Regulatory Science, Sree Siddaganga College of pharmacy B.H Road, Tumkuru-572102. Karnataka, India.

Review Article

World Journal of Advanced Research and Reviews, 2023, 20(01), 758-767

Article DOI: 10.30574/wjarr.2023.20.1.2079

DOI url: https://doi.org/10.30574/wjarr.2023.20.1.2079

Publication history

Received on 02 September 2023; revised on 12 October 2023; accepted on 15 October 2023

Abstract

Biologicals are restorative, therapeutic, analytic, preventive, arrangements created or got from living life forms and their turn for human use. Biological products are expected to continue to play a significant role in the future of medicine and health care. They include vaccines, serum, blood and blood products, gene therapy, antibodies, etc. The Indian administrative expert (CDSCO), is the body which is in charge of the advancement and promoting biologics in India. And in South Korea MFDS is responsible for regulations of biologics.

Objective: Unveiling the differences in regulatory approval aspects and documentation for biological products in India and South Korea as per CDSCO and MFDS respectively. Ensuring the safety, effectiveness, and quality of biological products requires various regulatory processes. These processes typically include rigorous testing, clinical Trails, quality control measure, and regulatory approvals by agencies like CDSCO in India and MFDS in South Korea. These steps are decisive to protect public health and ensure the biological products meet established standards before they made available to patients.

Keywords

Biological product; CDSCO; RCGM; GEAC; MFDS; KFDA; Comparative study; India; South Korea

Download Article PDF

https://wjarr.com/sites/default/files/fulltext_pdf/WJARR-2023-2079.pdf

Preview Article PDF

How to cite this article

Ashok kumar P, Divija P M, Reshma B R, Bhoomika K R and Ramya Shree R. Regulatory requirements for approval of biological products as per CDSCO in Indian comparison with South Korea. World Journal of Advanced Research and Reviews, 2023, 20(1), 758-767. Article DOI: https://doi.org/10.30574/wjarr.2023.20.1.2079

Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.

All statements, opinions, and data contained in this publication are solely those of the individual author(s) and contributor(s). The journal, editors, reviewers, and publisher disclaim any responsibility or liability for the content, including accuracy, completeness, or any consequences arising from its use.

Developed & Designed by VS Infosolution

Regulatory requirements for approval of biological products as per CDSCO in Indian comparison with South Korea

Ashok kumar P ^*, Divija P M, Reshma B R, Bhoomika K R and Ramya Shree R

Preview Article PDF

Get Certificates

Issue details

Regulatory requirements for approval of biological products as per CDSCO in Indian comparison with South Korea

Ashok kumar P *, Divija P M, Reshma B R, Bhoomika K R and Ramya Shree R

Preview Article PDF

Get Certificates

Issue details

Ashok kumar P ^*, Divija P M, Reshma B R, Bhoomika K R and Ramya Shree R